Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(9 sites)

China

Research Site, Beijing

Research Site, Changchun

Research Site, Guangzhou

Research Site, Hangzhou

Research Site, Suzhou

Research Site, Wenzhou

Research Site, Wuhan